These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37301758)

  • 1. Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial.
    Rymer JA; Wegermann ZK; Kaltenbach LA; Webb LE; Peterson ED; Wang TY
    J Am Heart Assoc; 2023 Jun; 12(12):e029063. PubMed ID: 37301758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Anstrom KJ; Fonarow GC; Henry TD; Cannon CP; Choudhry NK; Cohen DJ; Atreja N; Bhalla N; Eudicone JM; Wang TY
    Circ Cardiovasc Qual Outcomes; 2020 May; 13(5):e006182. PubMed ID: 32393129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 May; 5(5):532-539. PubMed ID: 32129795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs.
    Doll JA; Kaltenbach LA; Anstrom KJ; Cannon CP; Henry TD; Fonarow GC; Choudhry NK; Fonseca E; Bhalla N; Eudicone JM; Peterson ED; Wang TY
    J Am Heart Assoc; 2020 Apr; 9(8):e014975. PubMed ID: 32299284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    Wang TY; Kaltenbach LA; Cannon CP; Fonarow GC; Choudhry NK; Henry TD; Cohen DJ; Bhandary D; Khan ND; Anstrom KJ; Peterson ED
    JAMA; 2019 Jan; 321(1):44-55. PubMed ID: 30620370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
    Doll JA; Wang TY; Choudhry NK; Cannon CP; Cohen DJ; Fonarow GC; Henry TD; Bhandary DD; Khan N; Davidson-Ray LD; Anstrom K; Peterson ED
    Am Heart J; 2016 Jul; 177():33-41. PubMed ID: 27297847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial.
    Ho PM; O'Donnell CI; McCreight M; Bavry AA; Bosworth HB; Girotra S; Grossman PM; Helfrich C; Latif F; Lu D; Matheny M; Mavromatis K; Ortiz J; Parashar A; Ratliff DM; Grunwald GK; Gillette M; Jneid H
    J Am Heart Assoc; 2022 Jul; 11(13):e024342. PubMed ID: 35766258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS.
    Rymer JA; Kaltenbach LA; Peterson ED; Cohen DJ; Fonarow GC; Choudhry NK; Henry TD; Cannon CP; Wang TY
    J Am Heart Assoc; 2022 Oct; 11(20):e026421. PubMed ID: 36250667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.
    Fanaroff AC; Kaltenbach LA; Peterson ED; Akhter MW; Effron MB; Henry TD; Wang TY
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease.
    Rymer JA; Kaltenbach LA; Doll JA; Messenger JC; Peterson ED; Wang TY
    J Am Heart Assoc; 2019 May; 8(10):e012236. PubMed ID: 31070112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-practice gaps in P2Y
    Falster MO; Schaffer AL; Wilson A; Nasis A; Jorm LR; Hay M; Leeb K; Pearson SA; Brieger D
    Intern Med J; 2022 Feb; 52(2):249-258. PubMed ID: 32840951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
    Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
    JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome).
    Fosbøl EL; Ju C; Anstrom KJ; Zettler ME; Messenger JC; Waksman R; Effron MB; Baker BA; Cohen DJ; Peterson ED; Wang TY
    Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27789517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.